Park Ha Biological Technology publishes MD&A for six months ended April 30, 2026

• Park Ha Biological Technology published its MD&A for the six months ended April 30, 2026, showing revenue of $1,257,689, up 1%.
• Revenue mix shifted toward product sales at 57% from 33%, while franchise fees fell to 43% from 67%.
• Product sales rose 77% to $716,105, driven by higher non-franchise sales of $600,022, up 188%.
• Franchise-fee revenue dropped 35% to $541,584 as franchisees declined to 21 from 39; the model shifted to tighter admission standards.
• Net loss narrowed to $918,282 from $19.84 million; cash fell to $627,851 from $3.79 million, reflecting $5.02 million in short-term investments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Park Ha Biological Technology Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-081340), on July 24, 2026, and is solely responsible for the information contained therein.